Abstract: Myostatin is a negative regulator of muscle mass. Important advances in our understanding of the complex biology of this factor have revealed the therapeutic potential of antagonizing the myostatin pathway. Here we present the rationale for evaluating anti-myostatin therapies in human muscle-wasting disorders.
Publication Year: 2006
Publication Date: 2006-07-01
Language: en
Type: review
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 45
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot